Traditional Chinese medicine for treating primary PCI (percutaneous coronary intervention) postoperative poor myocardial perfusion of patients suffering from heart-qi deficiency type ST-segment elevation myocardial infarction

Abstract

The invention belongs to the technical field of medicines, and particularly relates to a traditional Chinese medicine composition for treating primary PCI (percutaneous coronary intervention) postoperative poor myocardial perfusion of patients suffering from heart-qi deficiency type ST-segment elevation myocardial infarction. The traditional Chinese medicine composition which is a traditional Chinese medicine comprises, by weight, 4-8 parts of nigella damascena, 4-8 parts of herba alyxiae sinensis, 4-8 parts of Phlegmariurushamiltonii (Spreng.) LoveetLovevar. petiolatus (Clarke) Ching, 4-8 parts of fructus psoraleae, 4-8 parts of semen ginkgo roots, 2-4 parts of meconopsis horridula, 4-8 parts of radix paeoniae alba, 4-8 parts of buddleja asiatica, 4-8 parts of plumbago indica and 4-8 parts of radix glycyrrhizae. The traditional Chinese medicine composition has the advantages that various medicines are used with one another, and accordingly effects of 'nourishing heart-qi and agitating heart vessels' can be jointly realized; myocardial perfusion of the patients suffering from the primary PCI postoperative poor myocardial perfusion and the STEMI (ST-segment elevation myocardial infarction) can be obviously improved.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a traditional Chinese medicine composition for treating heart-qi deficiency type ST-segment elevation myocardial infarction and poor myocardial perfusion after direct PCI. Background technique [0002] Direct percutaneous coronary intervention (Percutaneous coronary intervention PCI) is the main treatment for acute ST-segment elevation myocardial infarction (St-elevationmyocardialinfarctionSTEMI). However, it has been clinically found that about 30% to 40% of patients with infarct-related arteries do not improve myocardial tissue microcirculation perfusion, that is, myocardial perfusion is poor. Studies have found that myocardial perfusion is the main cause of cardiovascular events and mortality. Therefore, how to adopt which treatment method can improve myocardial perfusion after STEMI primary PCI has important clinical significance. [0003] Western medicine beli...

AI Technical Summary

Problems solved by technology

[0004] The technical problem to be solved by the present invention is to avoid the disadvantages of the above-mentioned prior art, and to provide a traditional Chinese medicine composition for treating heart-qi deficiency type ST-segment elevation myocardial infarction and poor myocardial perfusion after direct PCI